Tango Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 140
- Market Cap
- $1.2B
- Website
- http://www.tangotx.com
- Introduction
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Conditions
- PDACPDAC - Pancreatic Ductal AdenocarcinomaLung CancerPancreatic Cancer MetastaticThoracic CancerNSCLCRAS MutationMTAP Deletion
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT06922591
- Locations
- 🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇺🇸NYU Langone Health, New York, New York, United States
🇺🇸NEXT Dallas, Irving, Texas, United States
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Conditions
- Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, MalignantSolid TumorNon-Small Cell AdenocarcinomaLung CancerBrain Tumor
- Interventions
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 191
- Registration Number
- NCT06810544
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸NYU Langone Health, New York, New York, United States
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
- Conditions
- Pancreas CancerHRD Positive Advanced Ovarian CancerBreast CancerOvarian CancerBRCA1 MutationProstate CancerBRCA-Mutated Ovarian CarcinomaBRCA-Associated Breast Carcinoma
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT06065059
- Locations
- 🇺🇸
HealthONE, Denver, Colorado, United States
🇺🇸Mid Florida Cancer Centers, Orange City, Florida, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
- Conditions
- Non Small Cell Lung CancerSolid Tumors, AdultLung AdenocarcinomaLung Cancer
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05887492
- Locations
- 🇺🇸
NYU Langone Hematology Oncology Associates-Mineola, Mineola, New York, United States
🇺🇸UCLA Hematology/Oncology, Santa Monica, California, United States
🇺🇸SCRI at HealthOne, Denver, Colorado, United States
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT05732831
- Locations
- 🇫🇷
Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS, Saint-Herblain, France
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Grand Valley Oncology, Grand Junction, Colorado, United States
- Prev
- 1
- 2
- Next